Hepatocyte growth factor (HGF) promotes regeneration of the central nervous system, but its effects on the peripheral nervous system remain unclear. This study was conducted to elucidate the effect of HGF on regeneration of the murine facial nerve after crush injury. To do so, a replication-defective herpes simplex virus vector that incorporated HGF was prepared (HSV-HGF). The main trunk of the facial nerve was compressed by mosquito hemostats, and HSV-HGF, control vector or medium was then applied to the compressed nerve. We found that mice in the HGF group required significantly fewer days for complete recovery from nerve compression. Furthermore, the amplitude of the evoked buccinator muscle compound action potential increased following HSV-HGF application. HGF expression in and around the compressed nerve was demonstrated by enzyme-linked immunoassay and immunohistochemistry. In addition, HSV-HGF introduction around the damaged nerve significantly accelerated recovery of function of the facial nerve. These data suggest a possible role of HGF in promoting facial nerve regeneration after nerve damage. Furthermore, this viral delivery method may be applied clinically for many types of severe facial palsy during facial nerve decompression surgery.
INTRODUCTION
Numerous studies have used the facial nerve axotomy model to investigate the survival-promoting effects of neurotrophic and growth factors on axotomized motor neurons. Ciliary neurotrophic factor was the first factor to demonstrate motor neuronal survival following local application to lesioned axons in the newborn rat. 1 Subsequently, other neurotrophic and growth factors were found to prevent axotomyinduced motor neuron cell death, including neurotrophin-4/5, 2 insulin-like growth factor-1, 3 leukemia inhibitor factor, 3 brain-derived neurotrophic factor, 4 nerve growth factor, 5 neurotrophin-3 (ref. 6 ) and glial cell line-derived growth factor. 7 Although these neurotrophic factors have been shown to promote regeneration of the injured nerve, the functional outcomes have often been limited. 8, 9 Hepatocyte growth factor (HGF) is a disulfide-linked heterodimeric protein that was initially purified and cloned as a potent mitogen for hepatocytes 10, 11 and a natural ligand for the c-Met protooncogene product. 12 Subsequently, several functions have been ascribed to HGF, including anti-apoptosis, angiogenesis, motogenesis, morphogenesis, hematopoiesis, tissue regeneration in a variety of organs and enhancement of neurite outgrowth. [13] [14] [15] [16] [17] [18] [19] [20] Previous studies have reported that HGF protected neurons from damage and enhanced regeneration in the central nervous system in vivo. 13, [19] [20] [21] [22] [23] Given the known effects in the literature, HGF is thought to protect neurons from damage and promote peripheral nerve regeneration; however, little is known about its effects on the peripheral nerve systems.
Herpes simplex virus (HSV) type 1 vectors have been widely used for gene transfer of neurotrophic factors [24] [25] [26] [27] [28] because they are capable of infecting the cells of the nervous system. However, an inherent difficulty with HSV as a vector system lies in disabling the virus from being neurotoxic while maintaining its infection efficiency. To address this problem, we made a replication-defective HSV type 1 vector in which replication was disabled by deleting three critical genes for viral replication. [29] [30] [31] The availability of this vector has already been examined in the nervous system. [30] [31] [32] In the present study, we incorporated HGF into the replicationdefective HSV vector and inoculated murine facial nerves with the vector after compression. Here, for the first time, we demonstrate that HGF prevents peripheral nerve degeneration and promotes regeneration of facial nerve function in a murine model of crush injury.
RESULTS

Time course of facial nerve paralysis after compression
Facial nerve paralysis developed immediately after compression in all mice and then gradually improved and recovered completely by day 14. The time courses of facial scores for mice in each group are shown in Figure 1a . There was no significant difference in final facial scores on day 14 between mice in the LacZ and PBS groups. However, the facial scores for mice in the HGF group on days 7-12 were significantly higher than the scores for mice in the PBS and LacZ groups. We compared the number of days required to reach a score of 6, which indicates complete recovery from facial paralysis. The PBS group required 11.5±0.9 days, the LacZ group required 11.6±1.0 days and the HGF group required 10.3 ± 0.5 days (Figure 1b) . Recovery from facial nerve paralysis in the HGF group was significantly faster than in either the LacZ or the PBS groups (Po0.01, unpaired t-test). No mice died or showed any significant weight loss or other complications during this experiment.
Electrophysiological examination
The mean evoked compound muscle action potentials (CMAPs) amplitude of the buccinator muscle was 11.8 ± 1.1 mV in both groups combined before nerve compression. On day 7, CMAP amplitude decreased to 5.2 ± 0.3 mV (44%) in the LacZ group and 6.2 ± 0.6 mV (53%) in the HGF group (Figure 2a) . The decrease in CMAP amplitude was significantly larger (Po0.01, unpaired t-test) for the LacZ group than the HGF group. However, CMAP amplitudes increased between days 7 and 14 in both the LacZ and HGF groups. On day 14, the CMAP amplitude was 6.3 ± 0.3 mV (53%) in the LacZ group and 8.2 ± 0.6 mV (70%) in the HGF group. Furthermore, the HGF group showed significantly greater recovery of CMAP amplitude compared with the LacZ group (Po0.01, unpaired t-test). Finally, the difference in CMAP amplitudes between the HGF group and the LacZ group was larger on day 14 than on day 7.
HGF secretion in nerve extracts
The amount of HGF in the facial nerve before surgery was 1.62±0.11 ng (Figure 2b) . HGF in the LacZ group increased to 2.03 ± 0.95 ng on day 3 following surgery, then decreased to 1.56 ± 0.09 ng on day 7. HGF levels showed no significant differences on days 7-14 (1.59±0.11 ng measured on day 14). On the other hand, the HGF level in the HGF group increased to 2.31 ± 0.16 ng on day 3 and then decreased slightly to 2.08 ± 0.21 ng on day 7. This level was maintained until day 14 (2.11 ± 0.14 ng). Furthermore, HGF levels in the HGF group were significantly higher than levels in the LacZ group between days 3 and 14 (Po0.01, unpaired t-test). 
DISCUSSION
Neurotrophic factors have been proposed to be ideally suited for the treatment of neurodegenerative diseases, neuropathies and peripheral nerve injury. 33 However, administration of a growth factor into the body in solution form is not expected to be efficacious for tissue regeneration because of the short half-lives of growth factors. Hence, administration strategies should be based on transfer of genes, molecules or cells into the nervous system. Herpes simplex virus expressing nerve growth factor can be injected directly into the nerve and retrograde transported to mimic the physiological role of the neurotrophin coded for. This method has been shown to prevent the decrease in tyrosine hydroxylase activity seen in sympathetic ganglia after axotomy. 34 Similarly, administration of ciliary neurotrophic factor and brain-derived neurotrophic factor transduced in adenoviruses promotes the survival of neonatally axotomized motor neurons. 35 Although these experimental strategies were still in the early stages of development at the time of this study, they have demonstrated the potential of genetic manipulation for therapeutic application in the peripheral and central nervous system. Furthermore, these experiments demonstrated the possibility of modifying In the present study, we investigated the effect of HSV-HGF on crush nerve injury by compressing the facial nerve trunk. Previous studies have shown that, in murine models of facial nerve crush injury, reinnervation required 2 weeks, 36-38 which supports our findings. All mice recovered completely because nerve crush injury is a milder form of lesion than nerve transection and repair or avulsion with neurectomy. The pathophysiology of this nerve crush model was evaluated by facial movement score and CMAP. Facial movements were absent until day 4 and then recovered gradually by day 14. Therefore, the former period was the paralyzed phase, and the latter period was the recovery phase. CMAP amplitude was a quantitative indicator for evaluating Wallerian degeneration of the nerve after injury, as demonstrated by Esslen. 39 CMAPs on day 7 indicated that nerve degeneration was not completed and that functional nerve fibers still remained in both the LacZ and HGF groups. Histopathological findings also supported the presence of a mixture of intact, demyelinated and denervated fibers in the facial nerve trunk. Nerve degeneration on day 7 in the HGF group was less than in the LacZ group; CMAP amplitude was reduced to 56% in the LacZ group and 47% in the HGF group, suggesting that HGF prevented nerve degeneration. The difference in CMAP amplitudes between the LacZ and HGF groups was greater on day 14 (1.9 mV) than on day 7 (1.0 mV). This difference is thought to be attributed to the effect of HGF during nerve regeneration. Therefore, CMAP findings suggested that HGF affected the facial nerve by preventing degeneration and promoting regeneration. The CMAP amplitude did not recover to the preoperative level, although facial nerve paralysis recovered completely by day 14. This Figure 4 Images of the right facial nucleus of the HGF group. Facial nuclei were stained using the Klü ver-Barrera method (a) and stained for KT3 using immunohistochemical staining (b) on day 7. Black arrow shows the facial nucleus, but the KT3 antigen was not detected on day 7. Scale bars represent 100 mm. Figure 5 Magnified images of the right facial nerves of both groups, which were stained using the Klü ver-Barrera method. The top row shows images from the LacZ group on days 3 (a), 7 (b) and 14 (c) , and the bottom row shows images from the HGF group on days 3 (d), 7 (e) and 14 (f). On day 3, bulking myelin (arrows) was seen in the HGF group but not in the LacZ group. Almost all the myelin had degraded by day 7 for both groups, but some myelin regenerated in the HGF group. On day 14, more myelin (arrows) was regenerated in the HGF group than in the LacZ group. Schwann cells (arrowheads) were seen on days 3, 7 and 14 in both groups. Scale bars represent 10 mm.
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finding indicates that normal facial function can be restored without complete regeneration of the nerve fibers. A similar discrepancy between CMAP amplitude and recovery of facial nerve paralysis in the recovery phase was also reported in a mouse model of HSV neuritis 40 and in a human study of Bell's palsy. 41 Wild-type HSV type 1 is known to have affinity for neurons of the facial nerve and cause pathology in an animal model, 42 and the majority of Bell's palsy is caused by reactivation of HSV type 1 latently infected in the geniculate ganglion. 43 Therefore, the question facing gene transfer using the HSV vector is how to transfer genes effectively while avoiding neuropathogenesis. In this study, we negated its neuropathogenesis by deleting the genes encoding a4 and VP16, which are necessary for initiating viral replication, and g 1 34.5, which is a prerequisite for neuropathogenicity of HSV. 44 There are two methods for promoting regeneration of a crushed peripheral nerve using neurotrophins. One method is to apply the neurotrophins directly to the crushed nerve with bioresorbable materials, 8, 45 and the other method is to transfer genes by means of viral vectors. Other studies using HSV vectors have reported successful transfection of neurotrophins to the peripheral nerve nucleus. 26, 27 These authors disrupted neuropathogenesis of the vectors by deleting the genes encoding a4 and a27, which are essential to neuropathogenesis. However, these authors did not discuss the activity of neurotrophins at the site of the peripheral lesion. The uniqueness of our study came from successful HGF transfection into Schwann cells by directly applying the replication-defective HSV vector onto the crushed nerve. The transfected Schwann cells secreted HGF continuously, and the many known effects of HGF effectively prevented peripheral nerve degeneration and promoted nerve regeneration. HGF in the facial nerve extract increased on day 3 in all groups, including the LacZ group. The timing of the increase of HGF suggests a protective or regenerative function for the peripheral nerve. Although we measured the concentration of HGF over 14 days until the facial nerve recovered completely, another study of spinal cord regeneration, in which the same vector was injected into the spinal cord before compression, showed that the HGF increase was maintained for at least 4 weeks, and better functional recovery was observed. 21 In spinal cord injury, the mRNA expression levels of HGF and its receptor, c-Met, were reported to be upregulated. 21 Although we did not investigate the mechanism of how HGF affected the crushed nerve, the HGF-c-Met system seemed to be important for peripheral nerve injury. As further evidence, another mouse model in which incomplete regeneration is observed without treatment should be prepared to show the potential of HSV-HGF.
Collateral axonal branching is inevitable when nerves regenerate after an injury. In our study, axonal branching is thought to occur less often after transection and repair of peripheral nerves because crush injury is a milder lesion. As we did not transect, but crushed, the nerve, the paths for axon sprouting were preserved. Figure 5 shows the regeneration and formation of axons led by Schwann cells. When we investigate a mouse model of profound nerve injury in the future, marked collateral axonal branching is likely to occur at the site of lesion. Such excessive, redundant axonal branching is a major obstacle to the recovery of co-ordinated muscle function. Therefore, motion analysis is necessary to analyze the movement of the eye and vibrissae in detail to evaluate synkinesis. As mentioned above, another important consideration when using an HSV vector is avoiding neurotoxicity. In our model, cells transfected with HSV-HGF were not found in the facial nucleus, and no mice showed signs of encephalitis or other complications. These observations provide evidence for the safety of our vectors.
In a clinical context, our method can be applied in the treatment of selected patients with severe facial palsy caused by temporal bone fracture, Bell's palsy and Ramsay Hunt syndrome, all of which require decompression surgery. Decompression surgery is performed by opening the bony Fallopian canal, exposing the facial nerve and incising the nerve sheath. HSV-HGF can then easily be applied directly to the exposed injured nerve. However, the effect of decompression itself is limited even if performed with perfect timing. Therefore, application of our vector will likely provide even better surgical outcomes when decompression surgery is required.
MATERIALS AND METHODS
Preparation of HGF viral vector
Replication-defective HSV type 1 vectors were made by deletion of three critical genes for viral replication that encode a4, g 1 34.5 and VP16. These vectors contained an HSV latency-associated transcript (LAT) promoter and two enhancer elements, including a cytomegalovirus (CMV) enhancer and Woodchuck posttranscriptional regulatory elements (WPREs) (Figure 6 ). These vectors coded for LacZ (HSV-LacZ) or rat HGF (HSV-HGF), as described previously. 46 The former vector contained the CMV enhancer followed by the LacZ sequence, and the latter contained the full-length rat HGF complementary DNA tagged with the KT3 (large T antigen of simian virus 40) epitope. The two viruses were prepared with the same titers (1Â10 8 pfu ml À1 ).
Surgery and viral vector inoculation
Four-week-old specific-pathogen-free female Balb/C mice (14-16 g body weight; CLEA Japan, Inc., Tokyo, Japan) were used throughout this study. All mice were given food and water ad libitum. All experiments were approved by the University Committee in accordance with the Guidelines for Animal Experimentation of Nagoya City University (H17-21). Mice were anesthetized by intraperitoneal administration of ketamine (100 mg kg À1 ) and xylazine (10 mg kg À1 ). The main trunk of the right facial nerve was exposed below the parotid gland, released from the surrounding connective tissue, and compressed for 30 s using mosquito hemostats with a compression pressure of 6-8 MPa. Successful compression was confirmed by the lack of eye blink and whisker movement after surgery. After the operation, animals were divided into three experimental groups: HGF, LacZ and PBS. For the HGF group, 10 ml Figure 6 Schematic of HSV vector. Some of the genes required for viral growth in vitro (coding ICP4, ICP34.5 and VP16) were disrupted, and HGFKT3 (HGF tagged with KT3) or LacZ was inserted in the latency-associated-transcript (LAT) region.
(10 6 pfu) of HSV-HGF was applied to the compressed nerve. To avoid additional damage, HSV-HGF was carefully applied to the nerve with a micropipette. For the LacZ group, an equal volume of HSV-LacZ (10 6 pfu) was applied to the nerve, and for the PBS group, an equal volume of phosphate-buffered saline (PBS) was applied. Five minutes after virus application, the skin was closed with nylon suture.
Clinical evaluation of facial nerve paralysis
Body weight and clinical signs of facial nerve paralysis were monitored each day following nerve compression. To evaluate facial nerve paralysis, eye blink and whisker movement of each mouse were scored separately as previously described. 37 Specifically, for each facial area, a score of 0 was given for no detectable movement, 1 for detectable motion, 2 for significant but asymmetric voluntary motion and 3 for symmetric voluntary motion. Facial nerve function was determined by the total scores for eye blink and whisker movement.
Electrophysiology
CMAPs were evoked using conventional procedures with an electromyography monitor (UA-103U, Unique Medical Co., Ltd, Osaka, Japan) before surgery and on days 7 and 14 following surgery. Under anesthesia, the facial nerve was exposed, bipolar needles were hooked to the main trunk, and the nerve was stimulated supermaximally by single electrical pulses of frequency 1 Hz lasting 5 ms. Response amplitude was measured from peak to trough of the evoked response.
HGF from facial nerve extracts
The concentration of HGF was measured with enzyme-linked immunosorbent assay (ELISA) before surgery and on days 3, 7 and 14 after surgery. Under anesthesia with ketamine and xylazine, 3-mm-long segments of each facial nerve trunk, including the compressed site, were removed. They were rinsed 3 times with PBS, and sonicated in the solution that included 50 mM Tris-HCl, 2 M NaCl, 1% Triton X-100 and Protease Inhibitor Mix (GE Healthcare, Little Chalfont, UK). Thereafter, HGF was measured with rat HGF EIA (Institute of Immunology, Tokyo, Japan), as previously reported. 19, 46 This kit is known to react with mouse HGF because rat HGF has about 90.9% amino-acid sequence homology with mouse HGF. 47 Expression of the reporter protein around the inoculated nerve and in the facial nucleus Mice were transcardially perfused with 4% paraformaldehyde under deep anesthesia on day 3, 7 or 14. Following perfusion, the head was removed, decalcified in EDTA and embedded in paraffin. A portion of the facial nerve was obtained 1 mm distal to the compressed site. Sections 3 mm thick were stained by the Klüver-Barrera method. To detect transfected cells, immunohistochemistry for KT3 was used with a rabbit polyclonal anti-KT3 primary antibody (Bethyl Laboratories Inc., Montgomery, TX, USA) and an Envision+ system (Dako, Glostrup, Denmark) secondary antibody. Antibody binding was visualized by adding the chromogenic indicator dye DAB+ (Dako). Antibody specificity was confirmed using universal negative control rabbit immunoglobulin (Dako). The facial nucleus was also stained with the Klüver-Barrera method and immunohistochemistry staining for KT3. Images of sections were obtained via microscopy (Olympus Co., Ltd, Tokyo, Japan) with a CCD camera (Nikon, Co., Ltd, Tokyo, Japan). Frozen tissues were soaked in 20% sucrose in PBS at 4 1C overnight and frozen at À80 1C. Serial sections (12 mm) were cut using a cryostat. Dual immunofluorescence staining was used to confirm the colocalization of transfected cells and Schwann cells in frozen sections. Rabbit polyclonal anti-S-100 (Thermo Fisher Scientific Inc., Waltham, MA, USA) antibody and mouse monoclonal anti-KT3 antibody (Covance Research Products, Princeton, NJ, USA) were used in combination with Alexa Fluor 488-conjugated goat anti-mouse antibody and 546-conjugated goat anti-rabbit antibody (Invitrogen Corp., Carlsbad, CA, USA). 48 The images were obtained using confocal laser scanning microscopy (Leica Microsystems GmbH, Wetzlar, Germany).
Statistical analyses
Facial nerve score data were evaluated with Mann-Whitney tests, and other data were evaluated using unpaired t-tests in StatView Software (SAS Institute, Cary, NC, USA). Differences with a probability value of Po0.05 were considered statistically significant.
